Open AccessIL-17 mediates resistance to anti-VEGF therapy
Author(s) -
Eleni Maniati,
Thorsten Hagemann
Publication year - 2013
Publication title -
nature medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.536
H-Index - 547
eISSN - 1546-170X
pISSN - 1078-8956
DOI - 10.1038/nm.3333
Subject(s) - stromal cell , vegf receptors , vascular endothelial growth factor , cancer research , angiogenesis , medicine , tumor microenvironment , drug resistance , immunology , pharmacology , biology , tumor cells , microbiology and biotechnology
Interleukin-17 (IL-17) released in the tumor microenvironment in response to drugs blocking vascular endothelial growth factor (VEGF) triggers stromal-derived inflammatory and VEGF-independent angiogenic programs that induce the drug refractoriness found in cancers resistant to anti-angiogenic therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom